Hepatitis E cost-effectiveness of therapy: Difference between revisions
Joao Silva (talk | contribs) No edit summary |
Joao Silva (talk | contribs) No edit summary |
||
| Line 3: | Line 3: | ||
{{CMG}}; {{AE}} {{JS}} | {{CMG}}; {{AE}} {{JS}} | ||
==Overview== | ==Overview== | ||
[[Immunocompetent]] patients are usually able to clear [[HEV]] spontaneously, however, [[immunocompromised]] and end-stage [[liver disease]] patients may develop chronic hepatitis E. For this last group of patients, treatment is limited, and further studies are required to improve current therapy. Because these patients are at risk of developing [[complications]] from the disease, | [[Immunocompetent]] patients are usually able to clear [[HEV]] spontaneously, however, [[immunocompromised]] and end-stage [[liver disease]] patients may develop chronic hepatitis E. For this last group of patients, treatment is limited, and further studies are required to improve current therapy. Because these patients are at risk of developing [[complications]] from the disease, therapy and further investigations may be considered cost-effective. | ||
[[Blood transfusion]]s represent a rare form of [[transmission]] of hepatitis E. [[Screening]] of blood donations could help further decrease this risk. However, due to the fact that most patients are [[asymptomatic]], further studies are required to evaluate the cost-effectiveness of this measure.<ref name="pmid22549046">{{cite journal| author=Kamar N, Bendall R, Legrand-Abravanel F, Xia NS, Ijaz S, Izopet J et al.| title=Hepatitis E. | journal=Lancet | year= 2012 | volume= 379 | issue= 9835 | pages= 2477-88 | pmid=22549046 | doi=10.1016/S0140-6736(11)61849-7 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22549046 }} </ref> | [[Blood transfusion]]s represent a rare form of [[transmission]] of hepatitis E. [[Screening]] of blood donations could help further decrease this risk. However, due to the fact that most patients are [[asymptomatic]], further studies are required to evaluate the cost-effectiveness of this measure.<ref name="pmid22549046">{{cite journal| author=Kamar N, Bendall R, Legrand-Abravanel F, Xia NS, Ijaz S, Izopet J et al.| title=Hepatitis E. | journal=Lancet | year= 2012 | volume= 379 | issue= 9835 | pages= 2477-88 | pmid=22549046 | doi=10.1016/S0140-6736(11)61849-7 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22549046 }} </ref> | ||
Revision as of 03:42, 29 August 2014
|
Hepatitis E Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Hepatitis E cost-effectiveness of therapy On the Web |
|
American Roentgen Ray Society Images of Hepatitis E cost-effectiveness of therapy |
|
Risk calculators and risk factors for Hepatitis E cost-effectiveness of therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: João André Alves Silva, M.D. [2]
Overview
Immunocompetent patients are usually able to clear HEV spontaneously, however, immunocompromised and end-stage liver disease patients may develop chronic hepatitis E. For this last group of patients, treatment is limited, and further studies are required to improve current therapy. Because these patients are at risk of developing complications from the disease, therapy and further investigations may be considered cost-effective.
Blood transfusions represent a rare form of transmission of hepatitis E. Screening of blood donations could help further decrease this risk. However, due to the fact that most patients are asymptomatic, further studies are required to evaluate the cost-effectiveness of this measure.[1]
References
- ↑ Kamar N, Bendall R, Legrand-Abravanel F, Xia NS, Ijaz S, Izopet J; et al. (2012). "Hepatitis E." Lancet. 379 (9835): 2477–88. doi:10.1016/S0140-6736(11)61849-7. PMID 22549046.